CiVi Biopharma ApS: Financial statements 2022
CVR: 38027794
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
CiVi Biopharma ApS (CVR 38027794) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 3,530,115 and a net result of DKK 326,318 compared with DKK 344,004 the year before. That is a decrease of 12.5% compared with the year before. Equity in the 2022 report amounted to DKK 3,375,353. The solvency ratio was 85.5%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 3,530,115
- Profit/Loss
- DKK 326,318
- Equity
- DKK 3,375,353
- Total Assets
- DKK 3,947,544
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 3.5M | 326K | 3.4M | 1 |
| 2021 | - | 4M | 344K | 3M | 1 |
| 2020 | - | 4.5M | 392K | 2.7M | 1 |
| 2019 | - | 7.2M | 649K | 2.3M | 1 |
| 2018 | - | 6M | 707K | 1.7M | 1 |
Official annual report
Keep an eye on CiVi Biopharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
CiVi Biopharma ApS has published its annual report for 2021. Gross profit came to DKK 4,035,566, and the net result was DKK 344,004.
About CiVi Biopharma ApS
CiVi Biopharma ApS was a Danish company of the type Anpartsselskab based in København Ø, founded in 2016. The company has been dissolved on 5 February 2026. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CiVi Biopharma A/S. The company has 1 employee (2024). In 2024, the company reported a gross profit of DKK 610,531 and a net result of DKK -1,410,204 compared with DKK -1,887,334 the year before. Equity in the 2024 report amounted to DKK 77,815.